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A CD40 Signalosome Anchored in Lipid Rafts
Leads to Constitutive Activation of NF-B and
Autonomous Cell Growth in B Cell Lymphomas
tigen-activated immune accessory cells (Klaus et al.,
1999; Rush and Hodgkin, 2001).
Normal human B lymphocyte activation is a multistep
process, initially mediated by antigen recognition by
the cell surface receptor (BcR, SIg) and subsequent
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stimulating B cell activation, proliferation, and ultimately
cellular differentiation into antibody-producing plasma
cells (Berridge, 1997; Defranco, 1997). CD40 is a 45–50
Summary kDa member of the TNF- receptor (TNFR) family (Ban-
chereau et al., 1994) that is a comitogenic receptor ex-
B cell lineage non-Hodgkin’s lymphomas (NHL-B) are pressed on virtually all mature normal B lymphocytes,
neoplastic B cells that show dysregulated B lympho- as well as on most of their neoplastic B lineage counter-
cyte growth characteristics. Unlike normal B cells, ag- parts (Hsing et al., 1997; Wang et al., 1997). CD40 signal-
gressive NHL-B cells show constitutive expression of ing can also rescue IgM-cross-linked B cells from apo-
nuclear NF-B by maintaining an assembled, scaffold- ptosis, as well as being able to induce isotype switching
like signaling platform, called a Signalosome within in activated B cells (Burdin et al., 1995). CD40 is not
the lipid raft microdomain, extending from the cell B cell specific, however, as it is also expressed on a
membrane. The CD40 Signalosome appears to be initi- spectrum of other normal and neoplastic cell types, in-
ated through autochthonous production and cognate cluding some myeloid, dendritic, endothelial, and epi-
binding of CD154 (CD40L, gp39) to CD40 by the lym- thelial cells (Gaspari et al., 1996). CD40 ligand, or gp39
phoma cell. Constitutive expression of NF-B in NHL-B (CD154), is a 39 kDa TNF family, membrane-associated
can be downregulated by treatment with antibodies molecule that is transiently expressed as a trimer on
to CD40 or CD154 that disrupt Signalosomes, inhibit normal antigen-activated CD4 T cells (Armitage et al.,
lymphoma cell growth, and induce cell death. CD40 1993; Castle et al., 1993). It is involved in cognate inter-
Signalosomes may provide a potentially vulnerable actions with the membrane-bound CD40 receptor on
target for therapeutic intervention in NHL-B cells. B cells. CD154 normally functions as a costimulator of
B cell activation, although soluble isoforms (15, 18, 33
kDa) of CD154 have been described (Grammer et al.,Introduction
1999). CD40-CD154 interactions in B lymphocytes trig-
ger an intracellular pathway, characteristic of other TNFHigh-grade (aggressive) NHL-B cells are among the
family members, through TNF receptor-activating factorcommon forms of non-Hodgkin’s lymphoma (NHL)
2 (TRAF 2) followed by the IB kinase, IKK (Hsing etshowing significant increases in incidence during recent
al., 1997; O’Mahony et al., 2000), a component of thedecades. Aggressive NHL-B cells proliferate actively,
tripartate I-kappa kinase complex (IKK, , and ). Thisboth in vivo and when established in vitro, as part of
complex phosphorylates the IB/NF-B complex (Fran-their pathophysiology, with high proliferative rates being
cis et al., 1995; Karin and Ben-Neriah, 2000), leading toa negative clinical prognostic indicator (Joensu et al.,
subsequent IB ubiquitination and proteasome entry1990). Non-Hodgkin’s lymphoma B cells (NHL-B) retain
(Orian et al., 2000). Entry of this complex into the protea-many of the immunophenotypic characteristics of nor-
some in turn liberates NF-B from its cytoplasmic in-mal B lymphocytes (Kaleem et al., 2001), but generally
hibitor, IB (Winston et al., 1999), and exposes theshow three major differences: (1) monoclonality of tumor
previously concealed endogenous nuclear localizationB cells (Cleary et al., 1984), rather than the polyclonality
signal (NLS) for nuclear relocalization to the B sitesof normal B lymphocyte populations, best demonstrated
within NF-B target gene promotors (Palombella et al.,
through the expression of a single Ig idiotype (Stevenson
1994; Zhang et al., 2000). Constitutive NF-B has been
et al., 1993); (2) characteristic display of nonrandom
implicated in the development of a variety of human
chromosomal abnormalities (Klein, 1999) that place a cancers, including pancreatic, colon, and breast carci-
cell growth or viability-associated cellular oncogene un- nomas as well as in other types of lymphomas, including
der the control of a heterologous promotor or enhancer Hodgkin’s disease and T cell lymphomas (Sovak et al.,
(often the IgH enhancer in B cell lymphomas) that en- 1997; Nakashatri et al., 1997; Bargou et al., 1997; Mori
forces overexpression of the oncogene product (Tsuji- et al., 1999). Recently, pathways involved in cellular acti-
moto et al., 1984); and (3) lack of cellular growth regu- vation and growth in nonlymphoid cell types have been
lation, usually provided to normal B cells through shown to form a high molecular weight cytosolic com-
externally derived stimulatory signals obtained from an- plex, consisting of a scaffold-like concatenate molecular
structure called a Signalosome (Habib et al., 2001). This
structure contains the interactive component members4 Correspondence: rford@mdanderson.org
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of the EGF receptor signaling pathway (and may also
contain certain scaffolding proteins) in a single large
colocalizing organelle-like Signalosome structure that
compartmentalizes the particular pathway. This Sig-
nalosome may also sequester the pathway from other
potential interactions that could disrupt or negatively
regulate the pathway (Brown and London, 2000). Our
data indicate that the CD40 Signalosome is found in a
membrane lipid raft or microdomain, a cholesterol and
sphingolipid-rich, insoluble component of the cell mem-
brane that appears to anchor, aggregate, and activate
many of the important cell surface receptors and signal-
ing cascades in B cells (Simons and Ikonen, 1997; Bur-
ack and Shaw, 2000). In this study, we show that neo-
plastic human B cells display a unique internal signaling
mechanism involving “ectopic” production of the CD40
ligand (CD40L; CD154) through the utilization of a CD40-
anchored Signalosome contained within plasma mem-
brane-derived lipid rafts. This mechanism may allow
NHL-B cells to circumvent the requirement for externally
provided accessory cell-mediated cellular growth sig-
nals, required in the normal mature human B cell lineage.
This mechanism could allow aggressive B cell lym-
phoma cells to autonomously maintain the continuous
cell-cycling growth behavior, characteristic of these
neoplasms, through the Signalosome mechanism in-
volving the CD40/CD40L/NF-B cellular activation path-
way (Figure 7).
Results
Constitutive NF-B Activation in Aggressive
NHL-B Cells
Most normal lymphoid cells require a stimulatory input
from membrane cytokine receptors (e.g., TNF family) for
the activation and nuclear localization of the transcrip-
tion factor NF-B. To assess the status of NF-B in
aggressive NHL-B cells, we evaluated a series of aggres-
Figure 1. Expression of NF-B DNA Binding Activity in NHL-B Cellssive NHL-B cell lines, as well as freshly obtained biopsy-
by EMSAderived, aggressive NHL-B cells that had been in vitro
(A) 10 g of nuclear extract from normal human Go B cells (lane 1),purified to remove contaminating accessory (T lympho-
anti--treated B cells (lane 2), anti-- and rhCD154-treated B cellscytes, macrophages, etc.) cells. In Figure 1A, it can be
(lane 3), NHL-B cell lines (lanes 4–7), and cells from fresh patient
seen that both the NHL-B cell lines and the biopsy- biopsies (lanes 8–10) was subjected to EMSA with [32P]ds-NF-B
obtained NHL-B cells constitutively express NF-B oligo, as described in Experimental Procedures. The samples were
when subjected to electrophoretic mobility shift assay then subjected to a 6% nondenaturing acrylamide gel, electropho-
resed, dried, exposed to a phosphoimaging plate for at least 12 hr(EMSA) analysis. Normal resting purified peripheral
at RT, and then visualized using a phosphorimager.blood B lymphocytes do not express NF-B unless acti-
(B) For supershift, 10 g of NE of NHL-B cells was incubated withvated by cross-linking surface Ig molecules in the exog-
1 l of NF-B antibodies p50 (lane 4); p65 (lane 5); c-rel (lane 6);
enous presence of soluble CD40L (rhCD154). In Figure p52 (lane 7); a combination of p50, p65, and c-rel (lane 8); rel-B (lane
1B, a supershift assay using specific rel family antibod- 9); or 2 l cold probe (400 fmol/l ds-oligo) for competition (lane
ies indicates that predominantly the p50, p65, and c-rel 10) for 15 min at RT. 10 g of NE of a T cell Leukemia (Molt-4) was
used for negative control (lane 2), and 10 g of NE of NHL B cellssubunits of the NF-B proteins are bound in the shifted
was used for positive control (lane 3).complex, while the p52 and rel-B are not present. Since
(C) Supershift assay using patient biopsy nuclear extracts. 10 g ofthe NF-B complex observed in patient NHL-B cells
NE of patient 1 (Pat#1) was incubated with 1 l of NF-B antibodies
appears slightly different from that of the NHL-B cell p50 (lane 4), p52 (lane 5), p65 (lane 6), c-rel (lane 7), and rel-B (lane
lines, a supershift assay was performed on a representa- 8). For supershift analysis, the samples were subjected to a 4.5%
tive NHL-B patient biopsy sample. As indicated in Figure nondenaturing acrylamide gel and processed as described in (A).
1C, similar to NHL-B cell lines, in patient NHL-B cells,
the NF-B complex consists of p50, p65, and c-rel but
not p52 and rel-B. However, there are also two nonspe- Expression of CD40 and CD154 in NHL-B Cells
We have been unable to demonstrate abnormalities incific bands that are present in representative patient
NHL-B cells’ NF-B complex that are not present in the the distal CD40 pathway (IKK, IB, NF-B, etc.; data not
shown), suggesting that constitutive NF-B expressionNHL-B cell lines’ NF-B complex.
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has an upstream signaling source in aggressive NHL-B Involvement of Cell Membrane Lipid Rafts in
Anchoring the CD40 Signalosome in NHL-Bcells. Since all of the NHL-B cells studied show the
Cells and Normal B Lymphocytesconstant presence of cell membrane CD40, the expres-
The colocalization of CD40 and CD154 suggests that thesion of the proteins associated with the CD40 signaling
cell membrane-bound CD40 receptor and its cognatepathway were evaluated in aggressive NHL-B cells. In
ligand interact with the cytoplasmic CD40 signalingFigure 2A, it can be seen that when NHL-B cells are
pathway proteins within a spatially confined cellular or-subjected to Western blot analysis, not only the plasma
ganelle-like structure. This configuration suggests utili-membrane-associated CD40 receptor, but also the
zation of cell membrane lipid rafts (MLR), which haveCD40L (CD154) cognate ligand, is expressed. However,
recently been shown to associate with and encompassin unactivated Go normal B cells, CD40 and CD154 pro-
signaling pathway components of most major lympho-tein expression is lower and nonexistent, respectively,
cyte cell membrane receptors (Brown and London,when compared to anti-Ig and rhCD154-activated nor-
2000). To determine whether CD40 molecules and theirmal B cells (Figure 2A). To evaluate the expression of
components are present in membrane rafts, MLRs wereCD154 mRNA in NHL-B cells, reverse transcription-poly-
isolated from NHL-B cell lines, as nonsolubilized mem-merase chain reaction (RT-PCR) was performed that
brane in low-density fractions, after flotation in a Nyco-confirmed that CD154 mRNAs are expressed in NHL-B
denz gradient. CD40 protein and its cognate ligandcells from both NHL-B cell lines and purified patient
(CD154) were found to be present within the MLRs (Fig-NHL-B cell biopsies (Figure 2B). To further confirm the
ure 4A). The cell membrane raft-associated lipid, GM1-expression of CD154 protein in NHL-B cells, immunoflu-
ganglioside (CTxB), migrated toward the top of the Ny-orescence microscopy analysis was performed. As seen
codenz gradient as a biochemical marker for membranein Figures 2C and 2D, the expression of CD40 (red) and
lipid rafts. Other intracellular signaling proteins of theCD154 (green) are colocalized (yellow) subjacent to or
CD40/NF-B pathway, such as TRAF2, TRAF6, IKK/,within the plasma membrane at the cell periphery in
IB, and NF-B-p65, were also shown to exist withinboth NHL-B cell lines (Figure 2C) and patient lymphoma
the membrane lipid rafts (Figure 4B). In Figure 4C, it cancell biopsies (Figure 2D). In Figure 2E, NHL-B cells from
be seen that in normal human B lymphocytes, CD40one of the cell lines were labeled with CD40 (red) and
becomes associated with the MLR only upon cellular
TO-PRO-3 (blue) to demonstrate plasma membrane and
activation. Immunoflourescence microscopy images
nuclear labeling, respectively. Even though biopsy-
with Go B cells, double-labeled with anti-CD40 (red)
derived lymphoma cells were purified by immuno-deple-
and the lipid raft marker CTxB (green), displayed limited
tion and identified to be 98% CD20CD3, confocal expression of lipid rafts (Figure 4D). On cellular activa-
images were also stained with CD20 to verify that these tion of B lymphocytes, CD40 is activated and clustered
cells were in fact B cells (Figure 2F). within lipid rafts as demonstrated in Figure 4D. While
Coimmnoprecipitation studies demonstrate that, in normal B lymphocytes required exogenous cellular acti-
NHL B cells, the CD40 receptor and its components vation for membrane lipid raft clustering, NHL-B cells
interact with each other. As shown in Figure 3A, the (cell lines and patient lymphoma cell biopsies) constitu-
CD40-immunoprecipitated immune complex contains tively express lipid raft clustering (Figure 5A). The con-
CD40, TRAF2, and IKK. Since the coimmunoprecipita- centration of the CD40 receptor molecules and their
tion studies showed that some of the currently known intracellular signaling components in membrane lipid
components of the CD40 signaling pathway coprecipi- rafts was also examined by immunofluorescence confo-
tated, it was important to establish spatial data on the cal microscopy. NHL-B cells (cell lines and patient lym-
intracellular location of the pathway. The localization of phoma cell biopsies) were triple-labeled with polyclonal
the CD40 pathway proteins was then determined utiliz- anti-CD40 (cy3, red), CTxB (FITC, green), and either
ing immunofluorescence confocal microscopy to detect monoclonal antibodies to CD154, TRAF2, or NF-B-p65
the exact spatial location of the protein as well as its (cy5, blue). When all three images were merged, a white
relationship to the plasma membrane, nucleus, etc. In color appeared within the plasma membrane, indicating
Figure 3B, it can be seen that the CD40 receptor and that these molecules interact or colocalize within the
its cognate ligand, CD154, as well as TRAF2, IKK, and cell membrane lipid rafts (Figures 5B and 5C).
TRAF6, colocalize within or subjacent to the plasma
membrane. The high colocalization correlation coeffi- Antibody Disruption of the CD40 Signalosome
cient (average  0.9) for each panel indicates that the by Interdiction of CD40-CD154 Pathway:
two proteins being analyzed are closely coexpressed Downregulation of NF-B Inhibits Cell
and probably interactive. Confocal images obtained Growth and Induces Cell Death
from these studies indicate that a large organelle-like We hypothesize that the CD40 Signalosome is a linear,
body is present within or subjacent to the plasma mem- lipid raft-anchored, concatentate macromolecular com-
brane, containing all of the colocalized cytoplasmic plex of central importance in autonomous lymphoma
components of the CD40 signaling pathway (Figure 3B). cell growth that also maintains tumor cell viability by
To further confirm that these molecules are functionally preventing lymphoma cell death. If this model is valid,
as well as structurally bound as a macromolecular struc- interdiction or inactivation of the individual components
ture, an in vitro enzyme kinetics assay was performed of the CD40 signaling pathway should result in the dis-
that showed that the immunoprecipitated IKK, as well ruption of the complex, reversing the biologic effects
as the CD40-immunoprecipitated complex, can phos- of this signaling pathway. To test this hypothesis, we
treated NHL-B cells in vitro with antibodies to CD154phorylate the recombinant GST-IB (Figure 3C).
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Figure 2. Expression of the CD40 Receptor and Its Cognate Ligand CD154 in NHL-B Cells
(A) 100 g of protein lysates from Jurkat T cells (lane 1, positive control), normal human Go B cells (lane 2), activated normal B cells (lane 3),
NHL B cell lines (lanes 4–7), and fresh patient NHL-B biopsy cells (lanes 8–10) was subjected to 4%–15% SDS-PAGE, transferred onto PVDF
membrane, and probed with polyclonal antibodies against human CD40 and CD154 as indicated.
(B) CD154 mRNA expression in NHL-B cells by RT-PCR. The mRNA of CD154 was detected by using 2 g of total RNA from normal purified
human B cells (Go [lane 1], anti--activated [lane 2], and anti-- and rhCD154-activated [lane 3]) and NHL-B cell lines (lanes 5 and 7–10), and
cells from freshly purified patient lymphoma biopsies (lanes 4, 12, and 14) were reverse transcribed into cDNA and followed by 45 cycles of
PCR as described in Experimental Procedures. RNA isolated from Jurkat cells was used for positive control (lane 6), and PCR reaction minus
reverse transcriptase was used for negative control (lanes 11 and 13).
(C) Immunofluorescence microscopy analysis of CD40 and CD154. Paraformaldehyde-fixed NHL-B cell lines (MS, MZ, and LP) were costained
with polyclonal antibody against CD40 and monoclonal antibody against CD154 for 1 hr. Cells were then counter stained with donkey antibody
against rabbit (cy3-red, top panel) and goat antibody against mouse (cy2-green, middle panel) fluorescent secondary antibodies. Cells were
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alone, antibodies to CD40 alone, and in combination at aggressive NHL-B contributes significantly to the malig-
nant potential of the transformed cells in the pathophysi-different concentrations. In Figure 6A, it can be seen
ology of the disease process (Zelenetz et al., 1992).that antibody-treated cells stop proliferating and de-
Other important cellular growth-related pathways maycrease cell growth by approximately 80%. In two repre-
also be triggered by continuous CD40 stimulation (Bac-sentative experiments, when assayed and analyzed for
cam and Bishop, 1999), but NF-B expression appearsapoptosis by Annexin V staining and flow cytometry,
to be the central driving force in NHL-B cellular prolifera-NHL-B cells show an apoptotic population of 80%–90%
tion and viability maintenance in the representative lym-after treatment with antibodies to CD40 and/or CD154,
phoma cells that we have studied.as compared to untreated control of 10%–15% apo-
Identification of CD154 is not always easily demon-ptotic population (Figure 6B). Also, when the presence
strable in NHL-B in vitro (Younes and Carbone, 1999),of the CD40 Signalosome was assayed for by immuno-
due primarily to the often low-level expression of thefluorescence confocal analysis, anti-CD154 antibody
CD154 message and protein in NHL-B and normal rest-disrupted the CD40 Signalosome, as seen in Figure 6C,
ing, as well as activated, B lymphocytes (Figure 2), oftenwhere the presence of both the CD40 ligand (CD154)
requiring the screening of several primers from the 3	and the proximal TRAF2 can be seen to diminish. Anti-
end of the gene, as well as additional cycles of PCR toCD154 and CD40 antibody treatment also downregu-
adequately demonstrate experimentally (Pearson-Whitelates NF-B expression in NHL-B cells when analyzed
et al., 1995; Grammer et al., 1995; Gordon and Pound,by EMSA (Figure 6D). The correlation of lymphoma cell
2000). The lower CD154 message/protein levels ob-growth inhibition, tumor cell death, and disappearance
served in freshly obtained, purified NHL-B biopsy cellsof the CD40 Signalosome after in vitro treatment with
may indicate that NHL-B cell lines contain selected cellsantibodies indicates that this Signalosome plays an im-
from the tumor growth fraction that express relativelyportant role in growth and viability regulation in NHL-B
larger amounts of CD154 message/protein comparedcells.
with the total tumor cell population present in the patient
biopsy specimens. Exogenous CD154 stimulation is also
Discussion the basis of the so-called “CD40 system” that has been
described as an effective method for growing indolent
Aggressive neoplastic B cell growth, manifested through (low-grade) neoplastic B lymphoid cells in vitro for ex-
the loss of cellular growth regulation in high-grade tended time periods (Planken et al., 1996; Visser et al.,
NHL-B, is a fundamental biologic abnormality in aggres- 2000). Exogenous recombinant CD154 has also recently
sive lymphomas that significantly contributes to the been shown to be particularly effective in stimulating in
pathophysiology of these diseases (Willis and Dyer, vitro cell growth in primary Mantle cell NHL-B (Andersen
2000). Dysregulation of the proliferative potential in neo- et al., 2000). In a related B cell neoplasm, CLL, certain
plastic B cells has been shown to have clinical signifi- monoclonal antibodies to CD154 will not only inhibit
cance and has been recognized as a clinical prognostic CD40-CD154 binding, but also will downregulate consti-
factor (Coiffier et al., 2000), particularly in the high-grade tutive NF-B expression in the tumor cells (Schattner
NHL-B (large B cell lymphoma, immunoblastic, Burkitt’s, et al., 1998). This is particularly interesting, because
etc.). The presence of intact major cellular signaling antibodies to at least some CD40 epitopes are agonistic,
pathways such as CD40-CD154 in the cellular physiol- while antibodies to other epitopes, such as those used
ogy of NHL-B, as compared with their normal B cell in our studies, are antagonistic and show little or no
counterparts, implies that relatively subtle genetic or agonistic proliferative activity in vitro. Previous studies,
cellular signaling changes could account for signaling however, have indicated that not only can neoplastic
pathway dysregulation resulting in aberrant signaling B lymphoid cells be shown to express CD154 by flow
and unrestrained neoplastic B cell growth. In aggressive cytometry (Clodi et al., 1998), but that subsets of normal
large cell NHL-B, specific antigenic stimulation through B lymphocytes, including those resident primarily in
external accessory cells may be initially involved at an lymph node germinal centers, also constitutively ex-
early stage in the pathogenesis (Bahler and Levy, 1992), press CD154 (Grammer et al., 1999). The existence of
but such stimulation is ultimately unnecessary, due to such B cell subsets, however, indicates that an intact
acquisition of aberrant internal cellular signaling mecha- molecular mechanism for expressing the CD154 is pres-
nisms. This mechanism(s) bypasses important external ent in the normal B lymphoid cell lineage.
cellular growth regulatory signals provided to normal The term “Signalosome” is being used to describe
activated B lymphocytes by antigen-activated immune a membrane-associated macromolecular complex in a
accessory cells. The shift to cellular growth autonomy cellular signaling pathway, such as the IKK Signalosome
(Wallach et al., 1999). The IKK Signalosome, consists ofthat accompanies neoplastic cellular transformation in
visualized by Olympus FV500 laser scanning confocal microscope. Areas of colocalization are indicated in merged images as yellow color
(bottom panel).
(D) Freshly purified patient lymphoma biopsy cells (Pat #1 and Pat #2) were fixed with paraformaldehyde and stained with antibodies as in
(C). Colocalization of CD40 and CD154 is shown in merged images as yellow color (bottom panel).
(E) For control, NHL-B cells (MS) were labeled with anti-CD40 (cy3, red) and cy5-conjugated TO-PRO-3 (blue) for cell membrane and nuclear
staining, respectively.
(F) Freshly purified patient lymphoma biopsy cells were also stained with anti-CD40 (cy3, red) and cy5-conjugated CD20 (blue) for verification
of B cells.
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only IKK//, which can directly phosphorylate IB that the CD40 Signalosome itself may be an important
macromolecular target for future therapeutic approachesand IB. In lymphoid cells, NF-B-inducing agents
in human lymphomas.such as TNF utilize the IKK Signalosome, which appears
to function as an enzymic module for phosphorylating
Experimental ProceduresIB in TNF family signaling pathways that activate NF-
B (Song et al., 1997). Our studies suggest that, in ag- Cells and Reagents
gressive NHL-B, the CD40 Signalosome is anchored in Human NHL-B cell lines (MS, MZ, JM, and LP) were established
the lipid raft microdomains of the neoplastic B cell mem- from fresh patient biopsies as previously described (Ford et al.,
1990, 1995). Molt-4 T cell leukemia and Jurkat T cell lymphoma cellbrane by CD40 (Figure 7). Our confocal images also
lines were from ATCC (Manassas, VA). Cells were cultured in RPMIshow that the other component proteins, including
(GIBCO, Rockville, MD) containing 10% FCS. Fresh biopsy-derivedCD154, TRAFs 2 and 6, IKK (, , and ), IB, and NF-
lymphoma cells were obtained from lymph node biopsy specimens
B-p65, are present within the limits of the cell mem- from our Tissue Procurement and Banking core facility, and viable
brane microdomains. Details of the Signalosome ultra- single-cell preparations were enriched by SRBC rosetting followed
structure and its relationship to lipid rafts within the by “Rosette Sep” and contained 98% CD20 and
1% CD3 T cells
by flow cytometry analysis. Normal human B cells were purifiedplasma membrane are still not completely clear. Within
from donors’ buffy coats using an appropriate ratio of RosetteSep/the Signalosome itself, scaffolding proteins like IKAP
Human B Cell Enrichment Cocktail (Stem Cell Technologies, Van-appear to hold the structure together to some degree,
couver, Canada). Cells were incubated with the cocktail for 30 min
but also must interact with other components of the IKK at RT, underlayered with 15 ml of Ficoll-Paque PLUS (Amersham
Signalosome for enzymatic activity (Cohen et al., 1998). Pharmacia Biotech, Arlington Heights, IL), and centrifuged (1200 
g) for 20 min. Resulting cells were analyzed by flow cytometry andThe role of IKAP has recently been questioned (Krapp-
found to be 95%–98% CD20 positive. Purified B cells were activatedmann et al., 2000), but our studies have consistently
by incubating for 24 hr with anti- (3.5 g/ml/106 cells; ICN, Aurora,found this protein colocalized in the CD40 Signalosome
OH) and, in some cases, also with rhCD154 (1 g/ml; Alexis, San
(our unpublished data). Diego, CA).
Recently, Witte’s group has also described a Signalo-
some type of signaling mechanism involving Bruton’s Antibody Reagents and Materials
The following antibodies were purchased: polyclonal CD40 andtyrosine kinase (btk) and the B cell receptor (BCR) (Nisi-
CD40L, polyclonal and monoclonal IKK, IKK, IKK, IB, NF-tani et al., 1999). The concept has been further devel-
B-p50, -p52, and -p65, rel-B, c-rel, and TRAF6 (Santa Cruz, CA);
oped to include a Signalosome linking BCR stimulation phospho-IB mAb (New England Biolabs, Beverly, MA); mAb
with sustained Ca2 flux, possibly mediated through sta- CD154 (Pharmingen, San Diego, CA), mAb TRAF2 (Upstate Biotech,
bilization within cell membrane lipid rafts, in which the Lake Placid, NY); and secondary antibodies conjugated with Cy2,
Cy3, Cy5, and FITC (Jackson Immuno-Research Labs, West Grove,BCR and associated molecules, such as src family ki-
PA). Peroxidase-coupled and FITC-conjugated CTxB, Protein A/Gnases, associate after stimulation (Aman and Ravichan-
Sepharose, Nycodenz, and brij-58 detergent were purchased fromdran, 2000). As Witte’s group has recently pointed out, Sigma (St. Louis, MO). Recombinant GST-IB- substrate was pur-
these studies provide strong support for a Signalosome chased from Santa Cruz Biotechnology (Santa Cruz, CA).
model of B cell activation, and “a great likelihood that
In Vitro [3H]Thymidine Incorporation AssaySignalosomes are organized by other receptors on
In vitro thymidine incorporation proliferation assays were performedB cells” (Fruman et al., 2000). Our studies indicate that,
as described previously (Sundaresan et al., 1997). Cells were platedlike a number of other normal cellular physiologic mech-
as triplicate wells at 4  104 cells/well in 200 l RPMI, 10% FCS,
anisms that can be altered by neoplastic transformation with indicated antibody reagents in a 96-well culture plate and incu-
to the advantage of the tumor cell, the CD40 Signalo- bated in 5% CO2/air at 37C. After 24 hr, each well was pulsed with
0.5 Ci/10 l [3 H]thymidine (Amersham) and incubated for 16 hr;some can be coopted to mediate autonomous neoplas-
then, cells were harvested and counted in a Beckman LS3800 liquidtic cell growth. However, the ability to disrupt the CD40
scintillation counter.Signalosome with antibodies to the CD40 ligand (CD154)
or other component signaling proteins, leading to lym- Electrophoretic Mobility Shift Assays
phoma cell growth arrest (Funakoshi et al., 1994) as well Nuclear protein extraction and gel shift assay procedures were per-
formed as previously described by Chaturvedi et al. (1994). A 45-as the induction of significant tumor cell death, suggests
Figure 3. CD40 Signalosome Protein Components
(A) Coimmunoprecipitation. 500 g of NHL-B cell line cell (JM, MZ, and MS) lysates was incubated with 5 g of a polyclonal CD40 antibody
(lanes 2–4) or 5 g of an unrelated polyclonal antibody (lane 1) at 4C overnight. Immunocomplexes were precipitated by protein A-coupled
Sepharose beads and then subjected to 4%–15% SDS-PAGE, transferred to PVDF membranes, and probed for CD40, TRAF2, and IKK as
indicated.
(B) Colocalization of CD40/NF-B pathway components in cell membrane Signalosome. Immunostaining of CD40 and other components was
done as described in Experimental Procedures. Briefly, cells were fixed on a glass slide and costained with a polyclonal antibody against
CD40 (A1–D1) and monclonal antibody to CD154 (A2), TRAF2 (B2), IKK (C2), and TRAF6 (D2). These cells were then costained with the
appropriate donkey secondary antibodies conjugated to Cy2 or Cy3. Cells were then examined by confocal microscopy (Wallac UltraVIEW
LCI) for cellular localization. Images (A3)–(D3) represent overlays of images from (A1)–(D1) (red) and (A2)–(D2) (green) that show that CD40
and other components are colocalized in the yellow-appearing areas. The panels to the right (A4)–(D4) show the colocalization correlation
coefficient of these molecules, analyzed by UltraVIEW software.
(C) Co-IP and kinase assay. Jurkat T cell lysates (350 g) activated with TNF- (0.1 nM) for 30 min were incubated with 5 g of polyclonal
antibody to IKK (lane 1, positive control) or anti-CD40 (lane 7). Four NHL-B cell lines (JM, MZ, MS, and LP) were incubated with 5 g of
polyclonal antibodies to IKK (lanes 3–6), CD40 (lanes 9–12), or an unrelated antibody (lanes 2 and 8) at 4C overnight. Immunocomplexes
were precipitated with protein A-coupled Sepharose beads and then subjected to kinase assay with 5 Ci [-32P]ATP and 2 g of IB
substrate. Samples were analyzed by SDS-PAGE and autoradiography.
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Figure 4. CD40/CD154 and Signaling Proteins Are Associated with Lipid Raft Plasma Membrane Microdomains in NHL B Cells
(A) NHL-B cells (MS) (10  106 ) were lysed, and the lysates were subjected to Nycodenz density gradient fractionation for detection of signaling
pathway proteins in lipid raft microdomains, as described in Experimental Procedures. Gradient fractions, from low to high density (lanes
1–11), were subjected to 4%–15% gradient SDS PAGE, transferred to PVDF membranes, and then probed with CD40 and CD154 polyclonal
antibodies that were visualized by the ECL method. HRP-conjugated cholera toxin B (CTxB) was used as a marker for lipid raft protein and
was found in density fractions between 1 and 7.
(B) Raft fractions (1–7) and nonraft fractions were combined and subjected to Western blot analysis. Blots were probed with TRAF2, TRAF6,
IKK/, IB, NF-B-p65, actin (nonraft control), and CTxB (raft control).
(C) Go unactivated normal B cells do not express CD154 and display low CD40 protein expression as seen in Figure 1B. Lipid raft analysis,
as described in (A), indicates that in unactivated normal B cells, CD40 is not present in lipid rafts unless the B cells are activated (in this case
by anti-IgM and rhCD40L).
(D) Go normal B cells (left panel) and activated normal B cells (right panel) were fixed with paraformaldehyde and were costained with anti-
CD40 (red) and FITC-conjugated anti-CTxB (green). Immunofluorescence images were merged, and areas of colocalized CD40 in lipid rafts
are yellow as indicated.
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Figure 5. Plasma Membrane Lipid Raft Marker Colocalizes with CD40 and the Intracellular Signaling Pathway Molecules
(A) NHL-B cells (MZ and MS, left panel) and patient lymphoma cells (Pat #1 and Pat #2, right panel) were fixed with paraformaldehyde and
were stained with the lipid raft marker FITC-conjugated CTxB. Immunofluorescence images display clustering of lipid rafts (green) within the
lymphoma cell plasma membrane. (B) NHL-B cells (MZ) and (C) NHL-B patient cells (Pat #1) were fixed as described in Experimental Procedures
and were triple stained with anti-CD40 (a, red); CTxB (b, green); and anti-CD154, TRAF2, or p65 (c, blue) and analyzed by confocal microscopy.
Images were merged and areas of colocalization patterns were determined. Colocalizations of all three molecules appear as white color (f,
Merge All).
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Figure 6. Effects of Antibodies against CD40 and CD40L on Signalosomes in NHL-B Cells
(A) Proliferation assay. NHL-B cells were plated on a 96-well plate and incubated with antibody against CD40 (), CD40L (), both CD40 and
CD40L (), and an unrelated antibody () in a total volume of 200 l at 37C overnight. Cells were pulsed with 0.5 Ci/10 l of tritiated
thymidine, harvested after overnight incubation, and counted in a Beckman liquid scintillation counter.
(B) Annexin V apoptosis assay. NHL-B cells (0.7  106 cells/ml) were treated with CD40 Ab (histogram 2), CD154 Ab (histogram 3), or both
CD40 and CD154 Abs (histogram 4). Control and treated cells were labeled with annexin V FITC and PI staining and were analyzed on a FACS
Scan Analyzer equipped with Cell Quest software.
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Figure 7. Model: CD40 Signalosome Regulation of Neoplastic B Cell Growth
A schematic model of our current conceptual hypothesis of how the CD40 Signalosome is able to generate unrestrained cell growth in NHL-B
cells. In this model, the expression of the CD154 gene is dysregulated, and its ligand product continually binds to its cognate receptor CD40,
anchored in a lipid raft microdomain at the lymphoma cell membrane, through an internal feedback loop. This causes the CD40 Signalosome
to also be constitutively active within lipid rafts of the tumor cell membrane, providing continuous signaling for release of activated NF-B,
after release from the cytoplasmic inhibitor IB, which is removed and degraded in the proteasome. NF-B is necessary but not sufficient
for CD154 transcription, which also requires NF-AT and AP-1 transcription factors to bind the CD154 promotor. CD40 stimulation also activates
these transcription factors, as well as the inhibitory SMAD7 protein of the TGF/SMAD family of negative regulatory factors, but not through
the NF-B pathway. STAT6 and IL6 are also stimulated by CD40 stimulation by its cognate ligand and contribute to cell viability maintenance
(IL-6) and other characteristic stigmata of aggressive NHL-B in patients.
mer double-stranded NF-B oligonucleotide from the human immu- supershift, 1 l of NF-B supershift antibodies (Santa Cruz) p50,
p65, c-rel, p52, and rel-B were added to the NE 15 min before addingnodeficiency virus terminal repeat 5	-TTGTTACAAGGGACTTTCCG
CTGGGGACTTTCCAGGGAGGCGTGG-3	 was synthesized by GIBCO the labeled probe. For specificity, 2 l unlabeled oligonucleotide
(400 fmol/l ds-oligo) was used to compete out labeled probe. ForBRL and utilized for EMSA. For NF-B oligo labeling, 2 l of the 5	
oligo (1 pmol/l) was mixed (on ice) with 5 l of 10 T4 polynucleo- supershift analysis, the samples were subjected to a 4.5% nondena-
turing acrylamide gel.tide kinase buffer, 37 l H2O, 2 l [-32P]ATP (100 Ci/l), and 4 l
T4 polynucelotide kinase (total volume 50 l) and incubated at 37C
for 30 min. The reaction was stopped by adding 2 l of 0.5 M EDTA RT-PCR and Sequencing
Total RNA was obtained using RNAzolB as described by the manu-and purified by using a Sephadex G-50 column (Pharmacia). 1 l
of the 3	 oligo (100 pmol/l) was added to the labeled probe, boiled facturer’s instruction (TEL-TEST). 2 g total RNA was used to per-
form first strand cDNA synthesis by AMV reverse transcriptase usingfor 3 min, and annealed at RT for 15–30 min. The labeled ds-NF-B
probe was diluted at a concentration of 4 fmol/l. For each reaction, polydT primers (Gibco BRL). CD154 mRNAs were amplified from
100 ng cDNA, using the following oligonucleotides as primers:10 g of nuclear extract (NE) was incubated with 2 l of 10 binding
buffer, 2 l Poly dI:dC (1 g/l), 2 l 10% NP40, 4 l [32P]ds-NF-B 5	-CACCCTCTCGGACAGTTATTCA-3	 forward primer and 5	-GAT
AATTACAAGTTCACTCTGG-3	 reverse primer. The PCR conditionsoligo (4 fmol/l), and H2O (total volume of 14 l) at 37C for 15 min.
The samples were then subjected to 6% nondenaturing acrylamide are as follows: cDNA template was denatured at 95C for 1 min,
annealed at 48C for 30 s, and extended at 72C for 1 min per cycle,gel, electrophoresed, dried, exposed to a phosphoimaging plate for
at least 12 hr, and then visualized using a phosphorimager. For for 45 cycles. The PCR product (422 bp) was visualized on a 2.0%
(C) Disruption of the CD40 Signalosome by CD154 Ab. CD154 Ab-treated NHL-B cells were fixed on a glass slide and costained with antibody
to CD40 and CD154 (top panel) or CD40 and TRAF2 (bottom panel), then counter costained with appropriate fluorescent secondary antibodies
and visualized with confocal mircroscopy. Overlay of these stainings shows that these molecules are not colocalized (left panel), and the
correlation coefficient decreases significantly from as high as 90% (from Figure 4A) to as low as 52% for CD40/CD40L and 62% for CD40/
TRAF2 (right panel).
(D) Disruption of the Signalosome leads to the downregulation of NF-B by CD40/CD40L antibody treatments. 10 g of nuclear extracts from
treated and untreated cells was subjected to EMSA analysis. CD40/CD40L antibody treatment downregulates NF-B in a dose-dependent
manner: lanes 1 and 6 (untreated control), lane 2 (5 g/ml of anti-CD40), lane 3 (5 g/ml of anti-CD40L), lane 4 (preimmune serum), lane 5 (5
g/ml of unrelated antibody), and lanes 7–10 (1, 2.5, 5, and 10 g/ml CD154 Ab, respectively).
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